Skip to main content
Fig. 1 | BMC Ophthalmology

Fig. 1

From: Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents

Fig. 1

Our stepwise therapeutic approach for the patients with Behcet’s uveitis and distribution of the cases. *First Line Therapy: AZA: azathioprine, CS: corticosteroid, CsA: cyclosporine A, IFNα2a: interferon alpha2a, MTX: methotrexate. except one case. **Second Line Therapy: Interferon alpha2a. ***Third Line Therapy: ADA: adalimumab, Anti-TNF-α: Anti tumor necrosis factor alpha, INX: infliximab. ****Fourth Line Therapy: this line is used if necessary

Back to article page